Giapreza
Hepatorenal Syndrome
University of California, Los AngelesPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Hepatorenal Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
GLY-GLY-GLY-CYS-TYR-PHE-GLN-ASN-CYS-PRO-LYS-GLY-NH2 (4-9 DISULFIDE) Noorik Biopharmaceuticals AG | Phase 4 | A |
NORMAL HUMAN SERUM ALBUMIN Massachusetts General Hospital | Phase 4 | BBB |
Norfloxacin Hospital Clinic of Barcelona | Phase 4 | BB |
Octreotide Pamoate University of California, Los Angeles | Phase 2/3 | BB |
Midodrine University of California, Los Angeles | Phase 2/3 | BB |
View all 11 →
Same molecule, other indications
Giapreza is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →